Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Plan a withdrawal strategy post-rebalancing for SP 500 holdings to sustain income while managing risk.
24,074 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
An FDA leadership shakeup deepens as Tracy Hoeg publicly says she was fired, prompting questions about regulatory dir...
Trump Media’s underwater bitcoin moved to Crypto.com, fueling questions about how much of the reserve is freely held ...
Iovance Biotherapeutics has shown dramatic swings, with recent gains masking a long history of volatility. This piece...
Could SPGI be the global best wide-moat financial stock right now? This deep dive breaks down moats, competitive edge...
The private credit boom faces a real test as higher rates and shifting liquidity tighten the lending landscape. This ...
As year-to-date markets swing, Disney and PayPal stand out as potential rebound plays. This article weighs dividends,...
CrowdStrike faced a sharp sell-off for a second consecutive day after a sector-wide reaction to new AI security produ...
Kettle Hill Capital Management disclosed a new stake in RH, loading about 161,122 shares worth roughly $28.9 million....
SoFi stock faces a controversial short-seller narrative. This guide explains what that means, how to evaluate the cla...
April 2026 brings a new reality for buyers: higher mortgage costs, tighter lending, and more cautious optimism. This ...
A fresh stake in COPT Defense Properties signals a calculated tilt toward defense-related real estate. This article b...